Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 2009, p. 3103-3105, Vol. 53, No. 7
0066-4804/09/$08.00+0 doi:10.1128/AAC.00019-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.
Lon Protease Is Essential for Paradoxical Survival of Escherichia coli Exposed to High Concentrations of Quinolone 
Muhammad Malik,
Joseph Capecci, and
Karl Drlica*
Public Health Research Institute, New Jersey Medical School, UMDNJ, 225 Warren Street, Newark, New Jersey 07103
Received 6 January 2009/
Returned for modification 21 March 2009/
Accepted 29 April 2009

ABSTRACT
A deficiency of the
Escherichia coli Lon protease blocked paradoxical
survival occurring at very high nalidixic acid concentrations.
The absence of Lon also blocked a parallel increase in cell
lysate viscosity likely to reflect DNA size. Thus, Lon may participate
in repairing quinolone-mediated DNA lesions formed at high drug
concentrations.

INTRODUCTION
The quinolones are lethal antibacterials that form drug-gyrase/topoisomerase
IV-DNA complexes in which DNA is broken. Release of DNA ends
from protein-mediated constraint allows chromosome fragmentation
(
1,
9). An unexplained aspect of quinolone action is a paradoxical
increase in survival occurring at very high drug concentrations
(
2). To explore protease involvement in paradoxical survival,
we treated
Escherichia coli with nalidixic acid and examined
effects of
lon mutations on survival and on the presence of
chromosomal DNA lesions, the latter assayed by an empirical
measure of cell lysate viscosity. The Lon protease is known
to degrade damaged proteins and proteins produced in excess
(
15); it also serves as a chaperone (
6,
15). However, a role
in chromosome maintenance has not been reported. In the present
work a deficiency of Lon protease activity lowered survival
at high concentrations of nalidixic acid with little effect
at maximal bactericidal concentration.
E. coli K-12 strains, listed in Table 1, were grown in Luria-Bertani (LB) liquid medium and on LB agar plates (10) at 30°C; nalidixic acid was obtained from Sigma Chemical (St. Louis, MO). The effect of nalidixic acid was monitored by measuring lethal action and cell lysate viscosity (9). Lethal action was assayed by incubating exponentially growing cultures at 30°C for 180 min with nalidixic acid followed by drug removal using brief centrifugation, dilution, and enumeration of CFU by incubation on drug-free agar. Data were expressed relative to an untreated control taken at the time of drug addition. For viscosity, cell lysates were prepared as for isolation of bacterial nucleoids (cells were harvested by centrifugation, treated with lysozyme, and incubated for several minutes at 20°C with nonionic detergents [9]), and then sodium dodecyl sulfate was added to 0.8% to release DNA breaks from constraint by protein. Viscosity was estimated by measuring the time required to fill a 25-µl glass capillary (9) at several DNA concentrations to estimate specific viscosity.
We began by confirming general features of paradoxical survival:
it was observed with a variety of quinolones (nalidixic acid,
norfloxacin, and ciprofloxacin), several incubation temperatures
(30, 37, and 42°C), and two growth media (LB and nutrient
broth [not shown]). We also found that paradoxical survival
associated with nalidixic acid treatment was unaffected by a
noninducible
lexA3 mutation (not shown) or by concurrent chloramphenicol
treatment of a
gyrA67 gyrB225 mutant (Fig.
1) (the two gyrase
mutations separately interfere with the ability of chloramphenicol
to block quinolone-mediated killing [
7,
9]; together they show
strong paradoxical survival). Thus, neither the SOS response
(
8) nor protein synthesis is required for observation of paradoxical
survival, a phenomenon that is common to several different quinolones
and growth conditions.
To examine the involvement of Lon protease, we treated a
lon-deficient
strain (KD2372) with nalidixic acid at a variety of concentrations.
At maximal bactericidal concentrations, survival was similar
to that of wild-type cells, but at very high concentrations,
wild-type survival was about 3 orders of magnitude greater (Fig.
2A). Since accumulation of SulA (SfiA) causes
lon-deficient
mutants to be sensitive to DNA-damaging agents (
4,
5), we also
examined lethal action in a
lon sulA double mutant. Such a mutant
behaved similarly to a Lon-deficient strain, and a
sulA mutant
exhibited paradoxical survival similar to the wild-type strain
(Fig.
2B). Thus, paradoxical survival requires Lon activity
but not through its effect on SulA stability.
Lon protease has multiple domains, one functioning as an ATPase
and another as a protease (
16). We asked whether both or only
one Lon activity is required for paradoxical survival by using
mutant
lon genes expressed from plasmids. A
lon-deficient strain
(KD3037) containing the pBAD24 vector-only control showed little
paradoxical survival in the presence or absence of 0.1% arabinose,
the inducer used for this expression vector (Fig.
3A). These
data demonstrated that no plasmid component contributed to survival
at high quinolone concentration. When the plasmid contained
wild-type
lon (strain KD3045), paradoxical survival was observed
when arabinose was present but not when arabinose was absent
(Fig.
3B). A strain (KD3039) containing pBAD24
lon S679A that
lacked protease activity failed to show the paradoxical effect
(Fig.
3C), while a strain (KD3041) having pBAD24
lon K362Q deficient
in ATPase activity did (Fig.
3D). Neither strain showed paradoxical
survival in the absence of arabinose (Fig.
3C and D). These
data confirmed that Lon is necessary for paradoxical survival
and indicated that activity of its ATPase is dispensable. A
comparable experiment using complementation of UV sensitivity
and capsule overproduction as assays led to the conclusion that
protease activity rather than ATPase activity is dispensable
(
16). The reason for this difference is currently not understood.
An empirical viscometric assay was used to examine the effect
of nalidixic acid concentration on chromosomal quinolone-gyrase-DNA
complexes. Cells were exposed to various concentrations of nalidixic
acid, gently lysed, and treated with sodium dodecyl sulfate
to unfold chromosomes and release broken DNA from cleaved complexes.
Viscosity of lysates from cells exposed to various nalidixic
acid concentrations for 180 min exhibited a response similar
to that seen when survival was measured with both wild-type
and
lon-deficient cells (Fig.
4A). These data are consistent
with chromosomal DNA breaks being more prevalent when cells
are treated with bactericidal concentrations of nalidixic acid
than with much higher concentrations and with Lon playing a
role in reducing the number of DNA breaks.
Since quinolone-gyrase-DNA complexes form quickly after addition
of quinolone (
12), while cell death is a slower process (
9),
we also measured lysate viscosity after a brief, 15-min treatment
with nalidixic acid. Wild-type bacterial lysates exhibited a
minimum in viscosity that occurred at the same nalidixic acid
concentration as that with drug treatment for 180 min; when
drug concentration was very high, lysates from a
lon-deficient
mutant were less viscous than those from wild-type cells (Fig.
4B). Thus, cell death is not required for observation of
lon-dependent
changes in lysate viscosity.
In eukaryotic systems proteosome activity facilitates processing of DNA lesions generated by trapping of DNA topoisomerase II (18). Lon may serve a similar role for an undefined repair process with bacterial gyrase trapped on DNA by quinolones. In the present case, we observed the Lon effect only at very high concentrations of nalidixic acid, suggesting that complexes formed at high drug concentrations differ from those formed at optimal bactericidal concentrations. An understanding of the structural differences between complexes formed at optimal and at very high quinolone concentrations should help solve the paradox of increased survival at high quinolone concentrations. We are now examining Lon action biochemically to determine whether it acts directly on the complexes.

ACKNOWLEDGMENTS
We thank the following for critical comments on the manuscript:
Marila Gennaro, Susan Gottesman, Richard Pine, and Xilin Zhao.
We also thank Susan Gottesman for generously providing plasmids
and bacterial strains.
The work was supported by NIH grants AI35257, AI63431, and AI73491.

FOOTNOTES
* Corresponding author. Mailing address: Public Health Research Institute, New Jersey Medical School, UMDNJ, 225 Warren Street, Newark, NJ 07103. Phone: (973) 854-3360. Fax: (973) 854-3101. E-mail:
drlicaka{at}umdnj.edu 
Published ahead of print on 4 May 2009. 

REFERENCES
1 - Chen, C.-R., M. Malik, M. Snyder, and K. Drlica. 1996. DNA gyrase and topoisomerase IV on the bacterial chromosome: quinolone-induced DNA cleavage. J. Mol. Biol. 258:627-637.[CrossRef][Medline]
2 - Crumplin, G. C., and J. T. Smith. 1975. Nalidixic acid: an antibacterial paradox. Antimicrob. Agents Chemother. 8:251-261.[Abstract/Free Full Text]
3 - DiNardo, S., K. Voelkel, R. Sternglanz, A. Reynolds, and A. Wright. 1982. Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes. Cell 31:43-51.[CrossRef][Medline]
4 - Gayda, R., L. Yamamoto, and A. Markovitz. 1976. Second-site mutations in capR (lon) strains of Escherichia coli K-12 that prevent radiation sensitivity and allow bacteriophage lambda to lysogenize. J. Bacteriol. 127:1208-1216.[Abstract/Free Full Text]
5 - George, J., M. Castellazzi, and G. Buttin. 1975. Prophage induction and cell division in E. coli. III. Mutations sfiA and sfiB restore division in tif and lon strains and permit the expression of mutator properties of tif. Mol. Gen. Genet. 140:309-332.
6 - Gottesman, S. 1996. Proteases and their targets in Escherichia coli. Annu. Rev. Genet. 30:465-506.[CrossRef][Medline]
7 - Heddle, J., T. Lu, X. Zhao, K. Drlica, and A. Maxwell. 2001. gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity. J. Mol. Biol. 309:1219-1231.[CrossRef][Medline]
8 - Kelley, W. L. 2006. Lex marks the spot: the virulent side of SOS and a closer look at the LexA regulon. Mol. Microbiol. 62:1228-1238.[CrossRef][Medline]
9 - Malik, M., X. Zhao, and K. Drlica. 2006. Lethal fragmentation of bacterial chromosomes mediated by DNA gyrase and quinolones. Mol. Microbiol. 61:810-825.[CrossRef][Medline]
10 - Miller, J. 1972. Experiments in molecular genetics. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
11 - Miller, J. H., and K. B. Low. 1984. Specificity of mutagenesis resulting from the induction of the SOS system in the absence of mutagenic treatment. Cell 37:675-682.[CrossRef][Medline]
12 - Snyder, M., and K. Drlica. 1979. DNA gyrase on the bacterial chromosome: DNA cleavage induced by oxolinic acid. J. Mol. Biol. 131:287-302.[CrossRef][Medline]
13 - Sternglanz, R., S. DiNardo, K. A. Voelkel, Y. Nishimura, Y. Hirota, A. K. Becherer, L. Zumstein, and J. C. Wang. 1981. Mutations in the gene coding for Escherichia coli DNA topoisomerase I affecting transcription and transposition. Proc. Natl. Acad. Sci. USA 78:2747-2751.[Abstract/Free Full Text]
14 - Trisler, P., and S. Gottesman. 1984. lon transcriptional regulation of genes necessary for capsular polysaccharide synthesis in Escherichia coli K-12. J. Bacteriol. 160:184-191.[Abstract/Free Full Text]
15 - Tsilibaris, V., G. Maenhaut-Michel, and L. VanMelderen. 2006. Biological roles of the Lon ATP-dependent protease. Res. Microbiol. 157:701-713.[Medline]
16 - Van Melderen, L., and S. Gottesman. 1999. Substrate sequestration by a proteolytically inactive Lon mutant. Proc. Natl. Acad. Sci. USA 96:6064-6071.[Abstract/Free Full Text]
17 - Wall, J. D., and P. D. Harriman. 1974. Phage P1 mutants with altered transducing abilities for Escherichia coli. Virology 59:532-544.[CrossRef][Medline]
18 - Zhang, A., Y. Lyu, C.-P. Lin, N. Zhou, A. Azarova, L. Wood, and L. F. Liu. 2006. A protease pathway for the repair of topoisomerase II-DNA covalent complexes. J. Biol. Chem. 281:35997-36003.[Abstract/Free Full Text]
Antimicrobial Agents and Chemotherapy, July 2009, p. 3103-3105, Vol. 53, No. 7
0066-4804/09/$08.00+0 doi:10.1128/AAC.00019-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.